GT BiopharmaGTBP
13F holders, Q2 2024 (June 30)17holders +1
2new positions
1sold out
$35.30avg. 13F price*
At the end of Q2 2024, 17 institutions reported holding GT Biopharma Inc. (GTBP) in their 13F filings, up 1 from Q1 2024. 2 opened new positions and 1 sold out. The largest holders were DekaBank Deutsche Girozentrale ($37.8M), Bank of Montreal ($93K) and Susquehanna International Group, LLP ($54K).
- Company
- GT Biopharma Inc.
- CUSIP
- 36254L308
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $37.9M |
| Exits | 1 | $271 |
All 13F filers, Q1 2024 → Q2 2024: 1,015,310 shares bought and 10,592 shares sold, net +1,004,718 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 17 holders
| DekaBank Deutsche Girozentrale | 0.07% | New | 978,358 | $37.8M |
| Bank of Montreal | 0.00% | Add +50.3% | 29,872 | $93K |
| Susquehanna International Group, LLP | 0.00% | New | 18,984 | $54K |
| Geode Capital Management, LLC | 0.00% | No change | 11,184 | $32K |
| Vanguard Group Inc. | 0.00% | Reduce -48.8% | 10,504 | $30K |
| Wells Fargo & Company | 0.00% | Reduce -0.1% | 10,013 | $28K |
| BlackRock Inc. | 0.00% | Reduce -3.6% | 9,768 | $28K |
| UBS Group AG | 0.00% | Add +777.9% | 8,981 | $25K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -5.6% | 2,173 | $6K |
| Morgan Stanley | 0.00% | No change | 266 | $753 |
| Bank of America Corp. | 0.00% | Add +58.8% | 27 | $76 |
| Osaic Holdings, Inc. | 0.00% | Reduce -62.5% | 12 | $33 |
| Blue Bell Private Wealth Management, LLC | 0.00% | No change | 10 | $28 |
| BNP Paribas Financial Markets | 0.00% | No change | 6 | $17 |
| JPMorgan Chase & Co. | 0.00% | No change | 1 | $3 |
| Front Row Advisors LLC | 0.00% | No change | 1 | $3 |
| Royal Bank of Canada | 0.00% | No change | 7 | $0 |
"% of holder's portfolio" is GTBP's weight in each manager's 13F, not the share of GT Biopharma Inc. the manager owns.